Abstract Number: 2085 • 2016 ACR/ARHP Annual Meeting
Minding the Gap: the Use of Nurse Practitioners and Physician Assistants in U.S. Rheumatology Practice to Affect Rheumatology Workforce Shortages
Title: Minding the Gap: The Use of Nurse Practitioners and Physician Assistants in U.S. Rheumatology Practice to Affect Rheumatology Workforce Shortages Authors: Smith BJ1, Bolster…Abstract Number: 2086 • 2016 ACR/ARHP Annual Meeting
Hexagonal Phase Phospholipid Neutralization Assay Is the Most Sensitive but Least Specific Among Nine Tests for Detecting APS in SLE or Non-SLE Patients
Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune, hypercoagulable state which may elicit thrombosis and pregnancy loss. Although several tests exist to guide diagnosis of…Abstract Number: 2087 • 2016 ACR/ARHP Annual Meeting
A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome
Background/Purpose: In several autoimmune diseases, most notably in systemic lupus erythematosus (SLE), a type I interferon (IFN) signature has been described. This signature is thought…Abstract Number: 2088 • 2016 ACR/ARHP Annual Meeting
Rituximab Use in Pediatric Lupus Anticoagulant Hypoprothrombinemia Syndrome – Report of Three Cases and Review of the Literature
Background/Purpose: Lupus anticoagulant hypoprothrombinemia syndrome (LA-HPS) is a rare condition that may predispose to both thrombosis and bleeding due to positive lupus anticoagulant (LA) and…Abstract Number: 2089 • 2016 ACR/ARHP Annual Meeting
Deviation of T and B Cell Subset and Its Association with Single Nucleotide Polymorphisms in Patients with Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid syndrome (APS) is a well-characterized autoimmune and thrombotic disorder but its pathogenesis remains to be elucidated. Genomic studies have revealed the association of signal…Abstract Number: 2090 • 2016 ACR/ARHP Annual Meeting
Investigating the Genetic Variations of Antiphospholipid Syndrome By High-Throughput Exome Sequencing
Background/Purpose: The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies in serum together with clinical manifestations such as thrombosis,…Abstract Number: 2091 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Patients’ Time within Therapeutic Range of International Normalized Ratio (INR)
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic autoimmune disease characterized by recurrent arterial or venous thrombosis and/or recurrent pregnancy morbidities, with persistently positive antiphospholipid antibodies.…Abstract Number: 2092 • 2016 ACR/ARHP Annual Meeting
Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Is Elevated in Patients with Thrombotic Primary Antiphospholipid Syndrome.
Background/Purpose : Primary antiphospholipid syndrome (PAPS) is characterized by thrombotic and/or obstetrical morbidity in the presence of persistent antiphospholipid antibodies (APLA) and in the absence…Abstract Number: 2093 • 2016 ACR/ARHP Annual Meeting
Association of Conventional Risk Factors and Antiphospholipid Antibodies to Thrombosis in Patients with Autoimmune Diseases: Lessons Learned from a Year-Long Systematic Assessment
Background/Purpose: Patients with autoimmune disorders are at risk for thrombotic events and antiphospholipid antibodies (aPL) are one of known markers of increased thrombotic risk. The…Abstract Number: 2094 • 2016 ACR/ARHP Annual Meeting
Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
Background/Purpose: Complement activation is proposed as one of the major thrombophilic mechanisms in antiphospholipid syndrome (APS). Among three complement pathways (classical, alternative and lectin), activation…Abstract Number: 2095 • 2016 ACR/ARHP Annual Meeting
Autoantibodies Against High Density Lipoprotein-Associated Proteins Are Related to Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid Syndrome
Background/Purpose: Oxidized low-density lipoprotein (oxLDL), a key molecule in atherogenesis, serves as the source of anionic charged particles that bind to beta2glycoprotein I (Β2GPI) and…Abstract Number: 2096 • 2016 ACR/ARHP Annual Meeting
Venous Antiphospholipid Syndrome: Is the Unprovoked Nature of the 1st Thrombosis Associated with Clinical or Biological Features?
Background/Purpose: Risk of recurrence after a first episode of venous thrombo-embolism (VTE) is strongly correlated to VTE characteristics. Indefinite anticoagulation is recommended for patients with…Abstract Number: 2097 • 2016 ACR/ARHP Annual Meeting
Cardiolipin-Producing Candidate Commensals in the Gut Microbiome of Antiphospholipid Syndrome Patients
Background/Purpose: Pathogen-associated transient antiphospholipid antibodies suggest a microbial trigger for antiphospholipid syndrome (APS). We hypothesized that the gut microbiota could represent a chronic stimulus in…Abstract Number: 2098 • 2016 ACR/ARHP Annual Meeting
Non-Criteria Anti-Phospholipid Antibodies in SLE Patients
Background/Purpose: Current classification criteria for definite antiphospholipid syndrome (APS) recommend the use of one or more of three positive standardized laboratory assays, including anticardiolipin antibodies,…Abstract Number: 2099 • 2016 ACR/ARHP Annual Meeting
Micrornas As Potential Modulators of Atherothrombosis in Antiphospholipid Syndrome
Background/Purpose: 1) To identify and characterize microRNAs linked to thrombosis and atherosclerosis development in APS; 2) To assess the effects of antiphospholipid antibodies in that…
ACR Meeting Abstracts